291 related articles for article (PubMed ID: 9286755)
1. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
2. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
4. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
5. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
6. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
[TBL] [Abstract][Full Text] [Related]
7. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
[TBL] [Abstract][Full Text] [Related]
8. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
9. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
[TBL] [Abstract][Full Text] [Related]
10. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents.
James IE; Lark MW; Zembryki D; Lee-Rykaczewski EV; Hwang SM; Tomaszek TA; Belfiore P; Gowen M
J Bone Miner Res; 1999 Sep; 14(9):1562-9. PubMed ID: 10469285
[TBL] [Abstract][Full Text] [Related]
12. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
13. Effects of antisense mediated inhibition of cathepsin K on human osteoclasts obtained from peripheral blood.
Avnet S; Lamolinara A; Zini N; Solimando L; Quacquaruccio G; Granchi D; Maraldi NM; Giunti A; Baldini N
J Orthop Res; 2006 Aug; 24(8):1699-708. PubMed ID: 16795033
[TBL] [Abstract][Full Text] [Related]
14. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
16. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
17. A cytochemical assay for osteoclast cathepsin K activity.
Dodds RA
Cell Biochem Funct; 2003 Sep; 21(3):231-4. PubMed ID: 12910475
[TBL] [Abstract][Full Text] [Related]
18. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
19. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
20. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
